Role of arterial hypertension as a predictive marker for bevacizumab efficacy in recurrent glioblastoma – a prospective analysis

Figures & data

Table I. Results of the multiple Cox proportional hazards model for overall survival.

Predictor	Hazard ratio	95% CI	p-value
Bevacizumab-associated hypertension	1.72	(0.84–3.54)	0.14
KPS ≤ 80	0.77	(0.31–1.92)	0.57
Age < 55 years	0.30	(0.14–0.63)	0.001
Gender female	0.84	(0.39–1.82)	0.66

CI, confidence interval; KPS, Karnofsky performance status.

Figure 1. Overall survival after first dose of bevacizumab in patients with (solid lines) and without (dotted lines) bevacizumab-associated hypertension (p-value log rank test = 0.16). Bevacizumab associated hypertension was defined as 1) blood pressure of ≥ 140 mmHg systolic and/or ≥ 90 mmHg diastolic during the first 3 months after the start of bevacizumab in patients without prior hypertension, or 2) increase in systolic and/or diastolic blood pressure of > 10 mmHg during the first 3 months after the start of bevacizumab in patients with pre-existing hypertension. Censored patients (n = 4).